Literature DB >> 24858727

Polypharmacy in the treatment of subjects with intellectual disability.

Frank Häβler1, Johannes Thome, Olaf Reis.   

Abstract

People with intellectual disabilities often suffer from mental disorders or display challenging behavior. For both impairments, treatment with more than one psychopharmacological drug is common, although little is known about efficacy and side effects of polypharmacological treatment. The paper reviews studies on treatment of people with intellectual disability (ID) with more than one psychoactive drug. Many studies rely on poor evidence and are supplemented with data from our own research. Risks and benefits of different combinations containing neuroleptics are listed. Ethical considerations for the use of different drugs combined are discussed. The use of combinations of neuroleptics on people with ID should be carried out with great care, since side effects may be amplified in people with ID, depending on the combination.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24858727     DOI: 10.1007/s00702-014-1219-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  53 in total

1.  Statewide longitudinal survey of psychotropic medication use for persons with mental retardation: 1994 to 2000.

Authors:  Scott Spreat; James W Conroy; Amanda Fullerton
Journal:  Am J Ment Retard       Date:  2004-07

2.  International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities.

Authors:  Shoumitro Deb; Henry Kwok; Marco Bertelli; Luis Salvador-Carulla; Elspeth Bradley; Jennifer Torr; Jarret Barnhill
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

3.  Mental disorder in adults with intellectual disability. 2: The rate of behaviour disorders among a community-based population aged between 16 and 64 years.

Authors:  S Deb; M Thomas; C Bright
Journal:  J Intellect Disabil Res       Date:  2001-12

4.  Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability.

Authors:  Arlette Scheifes; Daniël de Jong; Joost Jan Stolker; Henk L I Nijman; Toine C G Egberts; Eibert R Heerdink
Journal:  Res Dev Disabil       Date:  2013-07-23

5.  Psychopharmacology and applied behavioral analysis: tandem treatment of severe problem behaviors in intellectual disability and a case series.

Authors:  Lee E Wachtel; Louis P Hagopian
Journal:  Isr J Psychiatry Relat Sci       Date:  2006       Impact factor: 0.481

Review 6.  Treatment of behavioral problems in intellectually disabled adult patients with epilepsy.

Authors:  Michael Kerr; Antonio Gil-Nagel; Michael Glynn; Marco Mula; Rose Thompson; Sameer M Zuberi
Journal:  Epilepsia       Date:  2013-03       Impact factor: 5.864

7.  The mental health of young children with intellectual disabilities or borderline intellectual functioning.

Authors:  Eric Emerson; Stewart Einfeld; Roger J Stancliffe
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-07-19       Impact factor: 4.328

Review 8.  Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation.

Authors:  A A Baumeister; M E Todd; J A Sevin
Journal:  Clin Neuropharmacol       Date:  1993-08       Impact factor: 1.592

9.  Psychotropic drug prescribing in child and adolescent learning disability psychiatry.

Authors:  David Bramble
Journal:  J Psychopharmacol       Date:  2007-04-19       Impact factor: 4.153

10.  Mental health of children and adolescents with intellectual disabilities in Britain.

Authors:  Eric Emerson; Chris Hatton
Journal:  Br J Psychiatry       Date:  2007-12       Impact factor: 9.319

View more
  7 in total

1.  Assessing the Impact of Psychotropic Medication Changes on Challenging Behavior of Individuals with Intellectual Disabilities.

Authors:  Maria G Valdovinos; Meara Henninger-McMahon; Elizabeth Schieber; Lisa Beard; Brenna Conley; Annette Haas
Journal:  Int J Dev Disabil       Date:  2016-04-28

2.  Psychotropic medication and psychotherapeutic treatment of adults with intellectual disabilities (PROMPT-ID): a cross-sectional, epidemiological study in Saxony, Germany.

Authors:  Andrea Koch; Julia Dobrindt; Matthias Schützwohl
Journal:  BMJ Open       Date:  2018-12-19       Impact factor: 2.692

3.  Effectiveness of medication reviews in identifying and reducing medication-related problems among people with intellectual disabilities: A systematic review.

Authors:  Amal Nabhanizadeh; Alyt Oppewal; Fleur Heleen Boot; Dederieke Maes-Festen
Journal:  J Appl Res Intellect Disabil       Date:  2019-02-22

4.  Community-Based Support and Social Services and Their Association with Frailty Factors in Older People with Intellectual Disability and Affective and Anxiety Disorders: A Swedish National Population-Based Register Study.

Authors:  Nadia El Mrayyan; Christina Bökberg; Jonas Eberhard; Gerd Ahlström
Journal:  Community Ment Health J       Date:  2021-11-08

5.  Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.

Authors:  Frank Haessler; Franziska Gaese; Michael Huss; Christoph Kretschmar; Marc Brinkman; Helmut Peters; Samuel Elstner; Michael Colla; David Pittrow
Journal:  BMC Psychiatry       Date:  2016-09-10       Impact factor: 3.630

6.  Anticholinergic burden in adult and elderly people with intellectual disabilities: Results from an Italian multicenter cross-sectional study.

Authors:  Luc Pieter De Vreese; Ulrico Mantesso; Elisa De Bastiani; Annachiara Marangoni; Elisabeth Weger; Tiziano Gomiero
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

7.  TOP-ID: a Delphi technique-guided development of a prescription and deprescription tool for adults with intellectual disabilities.

Authors:  Sophie Lonchampt; Fabienne Gerber; Jean-Michel Aubry; Jules Desmeules; Marie Besson; Markus Kosel
Journal:  BMJ Open       Date:  2020-11-04       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.